<nowiki>Ad5-nCoV; Ad5-nCoV; Ad5-nCOV; Convidecia; کانسینو; Ad5-nCoV; AD5-nCOV; Ad5-nCoV; Ad5-nCoV; Ad5-nCoV; Ad5-nCoV; Ad5-nCoV; Ad5-nCoV; എഡി5-എൻകോവ്; Ad5-nCoV; Convidecia; Ad5-nCoV; Ad5-nCoV; Ad5-nCoV; Ad5-nCoV; AD5-nCOV; Convidecia; Ad5-nCoV; vacuna de CanSino Biologics contra la COVID-19; COVID-19ワクチンの一つ; vacina para o covid-19; Chinese adenovirus-based vaccine against COVID-19; Chinese adenovirus-based vaccine against COVID-19; COVID-19疫苗; chinees COVID-19 vaccin; Convidecia; vacuna de CanSino; vacuna CanSino; vacuna de CanSino Biologics; PakVak; Convidecia; CanSino Biologics COVID-19 vaccine candidate; Convidecia; CanSino vaccine; PakVak; 克威莎; 克威莎2019冠状病毒病疫苗; Ad5-nCoV; vakcína od CanSino Biologics; Convidecia</nowiki>
Ad5-nCoV Chinese adenovirus-based vaccine against COVID-19
Carica un file multimediale Istanza di Sottoclasse di Fabbricante Sviluppatore Evento significativo phase I clinical trial (108, A Single-center,Open-label, Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old, dopo il 2020, –2021)
Aplicación de vacuna CanSino en la UAA.png 1 928 × 958; 1,63 MB
CanSino Convidecia.jpg 3 024 × 4 032; 2,58 MB
Pruebas de vacuna CanSino en México.png 1 280 × 720; 897 KB
.jpg)
